Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 14 studies | 27% ± 12% | |
glutamatergic neuron | 11 studies | 45% ± 26% | |
microglial cell | 11 studies | 37% ± 11% | |
astrocyte | 11 studies | 33% ± 13% | |
oligodendrocyte precursor cell | 10 studies | 28% ± 12% | |
GABAergic neuron | 9 studies | 37% ± 21% | |
fibroblast | 9 studies | 25% ± 9% | |
macrophage | 8 studies | 31% ± 11% | |
epithelial cell | 7 studies | 32% ± 15% | |
oligodendrocyte | 7 studies | 30% ± 9% | |
interneuron | 6 studies | 40% ± 22% | |
myeloid cell | 6 studies | 22% ± 8% | |
dendritic cell | 6 studies | 21% ± 5% | |
endothelial cell of lymphatic vessel | 6 studies | 29% ± 11% | |
neuron | 5 studies | 34% ± 11% | |
adipocyte | 5 studies | 22% ± 6% | |
ciliated cell | 5 studies | 26% ± 9% | |
T cell | 5 studies | 24% ± 7% | |
monocyte | 5 studies | 24% ± 6% | |
club cell | 5 studies | 30% ± 15% | |
smooth muscle cell | 5 studies | 19% ± 4% | |
type II pneumocyte | 5 studies | 30% ± 6% | |
basal cell | 5 studies | 30% ± 17% | |
deuterosomal cell | 4 studies | 22% ± 5% | |
squamous epithelial cell | 4 studies | 43% ± 21% | |
lymphocyte | 4 studies | 26% ± 11% | |
CD4-positive, alpha-beta T cell | 3 studies | 17% ± 1% | |
hematopoietic precursor cell | 3 studies | 25% ± 8% | |
GABAergic interneuron | 3 studies | 21% ± 5% | |
granule cell | 3 studies | 23% ± 4% | |
progenitor cell | 3 studies | 26% ± 2% | |
plasma cell | 3 studies | 27% ± 3% | |
cardiac muscle cell | 3 studies | 17% ± 1% | |
Mueller cell | 3 studies | 20% ± 4% | |
hepatocyte | 3 studies | 26% ± 11% | |
alveolar macrophage | 3 studies | 25% ± 7% | |
natural killer cell | 3 studies | 20% ± 3% | |
pericyte | 3 studies | 25% ± 7% | |
respiratory goblet cell | 3 studies | 30% ± 13% | |
transit amplifying cell | 3 studies | 37% ± 28% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5327.79 | 1445 / 1445 | 100% | 51.94 | 183 / 183 |
ovary | 100% | 2806.14 | 180 / 180 | 100% | 38.54 | 429 / 430 |
stomach | 100% | 2146.25 | 359 / 359 | 100% | 36.98 | 285 / 286 |
breast | 100% | 2785.93 | 459 / 459 | 100% | 57.30 | 1114 / 1118 |
intestine | 100% | 3216.84 | 966 / 966 | 100% | 33.05 | 525 / 527 |
lung | 99% | 2688.80 | 575 / 578 | 100% | 44.89 | 1154 / 1155 |
brain | 99% | 2954.53 | 2628 / 2642 | 100% | 46.58 | 703 / 705 |
bladder | 100% | 3083.19 | 21 / 21 | 99% | 37.75 | 498 / 504 |
prostate | 100% | 2983.60 | 244 / 245 | 99% | 39.06 | 497 / 502 |
uterus | 100% | 2944.32 | 170 / 170 | 98% | 39.22 | 452 / 459 |
pancreas | 99% | 1424.09 | 326 / 328 | 99% | 29.04 | 176 / 178 |
thymus | 100% | 2112.87 | 652 / 653 | 98% | 31.43 | 593 / 605 |
skin | 100% | 3829.28 | 1808 / 1809 | 97% | 46.07 | 459 / 472 |
kidney | 100% | 1754.62 | 89 / 89 | 96% | 22.35 | 865 / 901 |
adrenal gland | 100% | 2884.88 | 258 / 258 | 95% | 28.25 | 218 / 230 |
liver | 100% | 1391.62 | 226 / 226 | 91% | 20.43 | 371 / 406 |
adipose | 100% | 3104.09 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 26.46 | 29 / 29 |
muscle | 100% | 4958.71 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2036.75 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 14.32 | 1 / 1 |
blood vessel | 100% | 3900.41 | 1334 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 38.97 | 44 / 45 |
eye | 0% | 0 | 0 / 0 | 94% | 24.84 | 75 / 80 |
heart | 93% | 1608.35 | 800 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 92% | 1979.78 | 858 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0070373 | Biological process | negative regulation of ERK1 and ERK2 cascade |
GO_0007020 | Biological process | microtubule nucleation |
GO_0007010 | Biological process | cytoskeleton organization |
GO_1902993 | Biological process | positive regulation of amyloid precursor protein catabolic process |
GO_0065003 | Biological process | protein-containing complex assembly |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0016604 | Cellular component | nuclear body |
GO_0005875 | Cellular component | microtubule associated complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0005515 | Molecular function | protein binding |
GO_0031267 | Molecular function | small GTPase binding |
Gene name | RANBP9 |
Protein name | Ran-binding protein 9 (RanBP9) (BPM-L) (BPM90) (Ran-binding protein M) (RanBPM) (RanBP7) |
Synonyms | RANBPM |
Description | FUNCTION: May act as scaffolding protein, and as adapter protein to couple membrane receptors to intracellular signaling pathways (Probable). Acts as a mediator of cell spreading and actin cytoskeleton rearrangement . Core component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 . May be involved in signaling of ITGB2/LFA-1 and other integrins . Enhances HGF-MET signaling by recruiting Sos and activating the Ras pathway . Enhances dihydrotestosterone-induced transactivation activity of AR, as well as dexamethasone-induced transactivation activity of NR3C1, but not affect estrogen-induced transactivation . Stabilizes TP73 isoform Alpha, probably by inhibiting its ubiquitination, and increases its proapoptotic activity . Inhibits the kinase activity of DYRK1A and DYRK1B. Inhibits FMR1 binding to RNA. . |
Accessions | Q96S59 ENST00000011619.6 [Q96S59-1] |